News | Proton Therapy | September 02, 2022

The first of 396 patients has been enrolled into the PROTECT-trial with the aim of setting new standards for the clinical use of proton radiotherapy in esophageal cancer 

The first of 396 patients has been enrolled into the PROTECT-trial with the aim of setting new standards for the clinical use of proton radiotherapy in esophageal cancer

September 2, 2022 —  IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces that the PROTECT-trial consortium has enrolled the first patient in the PROTECT-trial investigating proton therapy in esophageal cancer.

The PROTECT (PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy) trial is a large-scale, multi-institutional, randomized controlled clinical trial, comparing the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced esophageal cancer, with the goal of improving outcomes for this group of patients. The trial was developed by the European Particle Therapy Network (EPTN). IBA is one of two leading industry collaborators involved in the trial. 

A total of 396 patients will be included in the randomized study with completion expected by 2027. A key objective of the PROTECT-trial is to reduce treatment related side effects and improve quality of life for the patients suffering from esophageal cancer. In addition, an important aspect of the study is to improve patient selection for proton therapy by evaluating existing selection criteria and creating shared guidelines for reimbursement. 

The PROTECT-trial consortium is a private-public collaborative project that includes 12 proton therapy centers, 17 academic partners, and more than 30 clinical trial sites across eight countries. 

Dr. Karin Haustermans, Co-chief Investigator and Medical Director of the Proton Therapy Center ParTICLe at UZ Leuven, Belgium, commented: "The PROTECT study will gather data on the benefits of proton therapy from multiple centers across Europe, for the first time. This sets the direction for the future use of proton therapy and could provide meaningful evidence for the benefits of proton therapy, which is needed to expand its use and identify the patients that benefit the most from treatment with protons."

Olivier Legrain, Chief Executive Officer of IBA, added: "We are pleased to see the PROTECT-trial consortium reaching its first significant milestone of starting patient recruitment. At IBA we are truly passionate about the benefits proton therapy can provide patients living with cancer, including reducing the side effects of treatment as well as improving quality of life whilst they receive it. We are very proud to be involved with the consortium and look forward to seeing the results of this study which we hope will produce high-quality clinical evidence on the advantages of proton therapy." 

For more information: www.iba-worldwide.com 

Find more content on ASTRO22 


Related Content

News | Oncology Information Management Systems (OIMS)

May 24, 2023 — RaySearch Laboratories AB announced that the oncology information system RayCare* (* subject to ...

Time May 24, 2023
arrow
News | ASTRO

May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages ...

Time May 23, 2023
arrow
News | Radiation Oncology

May 23, 2023 — ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that ...

Time May 23, 2023
arrow
News | Radiation Oncology

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
News | Radiation Oncology

May 18, 2023 — Cassling announced it is a new strategic sales agent in various geographic territories across the United ...

Time May 18, 2023
arrow
News | Radiation Oncology

May 16, 2023 — The American Society for Radiation Oncology (ASTRO) today expressed its strong support for President ...

Time May 16, 2023
arrow
News | Radiation Therapy

May 15, 2023 — GE HealthCare is presenting three new global innovations – Intelligent Radiation Therapy (iRT), Auto ...

Time May 15, 2023
arrow
News | Artificial Intelligence

May 8, 2023 — Artificial intelligence and machine learning (AI/ML) technologies are constantly finding new applications ...

Time May 08, 2023
arrow
News | Radiation Therapy

May 8, 2023 — Mirion, a leading provider of advanced radiation safety solutions, announced that it has updated the ...

Time May 08, 2023
arrow
News | Mammography

May 5, 2023 — The American College of Radiology (ACR), Breast Cancer Research Foundation (BCRF) and GE HealthCare ...

Time May 05, 2023
arrow
Subscribe Now